Abstract:Recombinant tissue plasminogen activator (rPA) has been used as a thrombolytic agent.However,considerable improvements have been done to prolong its plasma half-life (tl/2) and reduce its side effects,such as intracranial hemorrhage.Based on these improvements,a mutant of rPA,mrPA,was designed by mutating its PAⅠ-1 binding site to extend its t1/2.Furthermore,a fusion protein conjugating mrPA with NR3 was designed,which was a rAcAp5 mutant with a platelet GPⅡb/Ⅲa-binding RGD motif,to enhance the ability of targeted-thrombus and thrombolysis.The synthesized DNA sequences coding the two proteins were amplified by PCR,cloned into pET30a to construct recombinant plasmids pET30a-mrPA and pET30a-mrPA-NR3,and transformed into E.coli BL21 (DE3).The two proteins were expressed in inclusion bodies induced by isopropyl ｀-D-1-thiogalactopyranoside.After purified to qualified purity using one-step Ni affinity chromatography,the denatured proteins were refolded by dialysis.Their thrombolytic effects in vitro and in vivo were evaluated.In vitro 3.5 and 7 μmol/L of mrPA significantly reduced thrombus weight;1.75,3.5 and 7 μmol/L of mrPA-NR3 also significantly reduced the thrombus weight,and mrPA-NR3 displayed stronger thrombolytic effects than mrPA at 7 μmol/L.In vivo both mrPA and mrPA-NR3 showed significantly thrombolytic effect at 60-240 μmol/kg in thrombolytic model of inferior vena cava.Importantly,mrPA-NR3 exhibited more potent thrombolytic effect than both mrPA and rhM-tPA (positive control) at 240 μmol/kg.In addition,these two novel proteins did not increase bleeding time while they exerted thrombolytic effect.In conclusion,we engineered two novel proteins and proved that fusion protein had better thrombolytic effect than non-fusion protein,and the results suggest that dual thrombolytic mechanism or thrombus-target potentiated the thrombolytic effect of rPA and alleviated hemorrhage side reaction.This study may shed light on the development of novel thrombolytic agents with targeted thrombolysis and reduced side effects.

A Novel Recombinant Fusion Protein Exhibited Inhibitory Activities on Platelet Aggregation and Thrombin

A Novel Hirudin Derivative Characterized with Anti-Platelet Aggregations and Thrombin Inhibition.

Efficient targeted anticoagulant with active RGD motif.

A Novel Anti-Platelet Peptide (Z4A5) Potential for Glycoprotein IIb/IIIa Inhibits Platelet Aggregation

Design, Preparation and Activity Evaluation of Novel Recombinant Thrombolytic Proteins

[Fermentation, Purification and Identification of Recombinant RGD-Hirudin].

In situ formed depot of elastin-like polypeptide-hirudin fusion protein for long-acting antithrombotic therapy

Engineering a “three-in-one” hirudin prodrug to reduce bleeding risk: A proof-of-concept study

Expression, Purification, and Mass Spectrometric Analysis of 15N, 13C-Labeled RGD-hirudin, Expressed in Pichia Pastoris, for NMR Studies.

Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus

RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection

Improving long circulation and procoagulant platelet targeting by engineering of hirudin prodrug

Prokaryotic Expression of SA-hirudin-RGD Fusion Proteinand Identification of Its Anticoagulant and Anti-platelet Aggregation Function

Engineering Factor Xa Inhibitor with Multiple Platelet-Binding Sites Facilitates its Platelet Targeting

Modulation Of Platelet Activation And Thrombus Formation Using A Pan-Pi3k Inhibitor S14161

Molecular cloning of hirudin derivative cDNA gene and expression in mammalian cell

Construction and Expression of Chimeric Antithrombotics with Hirudin and RGD Sequence

Structural basis of RGD-hirudin binding to thrombin: Tyr 3 and five C-terminal residues are crucial for inhibiting thrombin activity

Structure-guided Creation of AcAP5-derived and Platelet Targeted Factor Xa Inhibitors

Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding

RGD and Scutellarin Conjugate (WK001) Targeting Platelet Glycoprotein IIb/IIIa Receptor Protects from Myocardial Ischemia/Reperfusion Injury: Synthesis, Characterization, and Bioactivity Evaluation